Advertisement

ADVERTISEMENT

Ovarian Cancer

Mostafa Eyada, MD, University of Texas, Medical Branch
Videos
Bevacizumab Plus Oral Cyclophosphamide Demonstrated Safety, Efficacy Among Patients With Recurrent Platinum-Resistant Ovarian Cancer
06/19/2024
Mostafa Eyada, MD
Mostafa Eyada, MD, describes a retrospective analysis assessing the safety and efficacy of bevacizumab plus oral cyclophosphamide among patients with recurrent high-grade platinum-resistant ovarian, fallopian tube, and primary peritoneal...
Mostafa Eyada, MD, describes a retrospective analysis assessing the safety and efficacy of bevacizumab plus oral cyclophosphamide among patients with recurrent high-grade platinum-resistant ovarian, fallopian tube, and primary peritoneal...
Mostafa Eyada, MD, describes a...
06/19/2024
Oncology
Frederik Marmé, PhD, Heidelberg University
Videos
Atezolizumab Plus Chemotherapy and Bevacizumab Did Not Improve Survival For Patients With Recurrent Platinum-Resistant Ovarian Cancer
06/13/2024
Frederik Marmé, MD, PhD
According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant...
According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant...
According to phase 3 data, the...
06/13/2024
Oncology
Conference Coverage
Batiraxcept Plus Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer
06/13/2024
Allison Casey
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results, batiraxcept plus paclitaxel did not improve the survival outcomes among the overall cohort of patients with platinum-resistant ovarian cancer, but may benefit patients with AXL-high expression.
According to phase 2 results,...
06/13/2024
Oncology
Conference Coverage
Suvemcitug Plus Chemotherapy Improved Survival Outcomes Among Patients With Platinum-Resistant Ovarian Cancer
06/13/2024
Allison Casey
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES trial found suvemcitug plus chemotherapy improved the progression-free survival, objective response rate, and disease control rate among patients with platinum-resistant ovarian cancer.
Results from the phase 3 SCORES...
06/13/2024
Oncology
Quiz: Does Hydroxychloroquine Plus Itraconazole Display Antitumor Activity in Advanced EOC?
07/29/2021
Although hydroxychloroquine plus itraconazole was feasible in heavily pre-treated patients with platinum-resistant epithelial ovarian cancer, the regimen did not demonstrate antitumor activity.
Although hydroxychloroquine plus itraconazole was feasible in heavily pre-treated patients with platinum-resistant epithelial ovarian cancer, the regimen did not demonstrate antitumor activity.
Although hydroxychloroquine plus...
07/29/2021
Oncology
Katrine Wallace, PhD, MS
Videos
Real-World Utilization of Second-Line Maintenance Therapy for Advanced Ovarian Cancer
07/19/2021
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.
Katrine Wallace, PhD, MS,...
07/19/2021
Journal of Clinical Pathways
Conference Coverage
Real-World PFS Among Patients With Ovarian Cancer Receiving First-Line Maintenance Therapy vs Active Surveillance
07/14/2021
Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.
Though most patients with ovarian cancer do not receive first-line maintenance therapy, those who do may be more likely to experience improved PFS.
Though most patients with...
07/14/2021
Journal of Clinical Pathways
Richard Penson, MD, MRCP, Discusses Recent Advancements in the Treatment of Ovarian Cancer
Videos
Richard Penson, MD, MRCP, Discusses Recent Advancements in the Treatment of Ovarian Cancer
07/01/2021
Dr Penson provides an overview of the latest evidence-based data regarding surgical and pharmacologic ovarian cancer treatment.
Dr Penson provides an overview of the latest evidence-based data regarding surgical and pharmacologic ovarian cancer treatment.
Dr Penson provides an overview...
07/01/2021
Oncology
Conference Coverage
Cost-Effectiveness of Two Testing Strategies for BRCA Mutations in Ovarian Cancer
06/23/2021
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
A study presented at the virtual 2021 ASCO Annual Meeting compared the cost-effectiveness of two testing strategies for patients with ovarian cancer.
A study presented at the virtual...
06/23/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Patterns and Predictors of First-Line Maintenance Therapy Use in Ovarian Cancer
06/23/2021
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
First-line maintenance therapy use for ovarian cancer has increased over time, particularly among patients with biomarker guidance.
First-line maintenance therapy...
06/23/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use